AzTrials
AzTrials

X-Linked Retinitis PigmentosaXOLARISNCT04926129

Natural History of the Progression of X-Linked Retinitis Pigmentosa

An observational study of X-Linked Retinitis Pigmentosa, run by NightstaRx Ltd, a Biogen Company at 22 sites in 7 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of the study is to gain a better understanding of disease progression over time in participants with X-linked retinitis pigmentosa (XLRP). Read more about this study

Who is it for?
Ages 7 years and older
Conditions the study is for
X-Linked Retinitis Pigmentosa
What is being tested?
Other: Assessments
How many people
201 participants
Where
22 sitesin 7 countries
Study dates
13 Sep 2017to 16 Dec 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: 201 participants with X-linked Retinitis Pigmentosa (XLRP).

Who may be able to join

  • Have documentation of a pathogenic mutation in the retinitis pigmentosa GTPase regulator (RPGR) gene.
  • Are willing and able to undergo ophthalmic examinations, as required by protocol, for up to 24 months
  • Have an ETDRS BCVA in at least 1 eye of ≥34 letters (Equivalent to Snellen ≥ 6/60 or 20/200; decimal 0.1; LogMAR 1.0).
  • Mean retinal sensitivity in the eligible eye as assessed by microperimetry:
  • Males with a mean retinal sensitivity of 68 loci ranging from ≥0.1 decibels (dB) and ≤20 dB.
  • Females with a mean retinal sensitivity of 68 loci ranging from ≥0.1 dB and ≤25 dB.
  • If female, have symptomatic disease with impairment of visual function.

Who cannot join

  • Have a history of amblyopia in the eligible eye.
  • Have any other significant ocular or non-ocular disease/disorder which, in the opinion of the investigator, may put the participant at risk because of participation in the study, may influence the results of the study, may influence the participant's ability to perform study diagnostic tests, or impact the participant's ability to participate in the study. This includes clinically significant cataracts.
  • Have participated in another research study involving an investigational medicinal product in the past 12 weeks or received a gene/cell-based therapy at any time previously (including but not limited to Intelligent Implant System implantation, ciliary neurotrophic factor therapy, nerve growth factor therapy).
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Trial locations and contacts

22 sites in 7 countries.

22 sites in 7 countries

United States10 sites
  • Research Site

    Dallas, Texas, 75231

  • Research Site

    Houston, Texas, 77030

  • Research Site

    Los Angeles, California, 90095

  • Research Site

    Madison, Wisconsin, 53705

  • Research Site

    Miami, Florida, 33136

  • Research Site

    New York, New York, 10032

  • Research Site

    Phoenix, Arizona, 85020

  • Research Site

    Portland, Oregon, 97239

  • Research Site

    Salt Lake City, Utah, 84132

  • Research Site

    San Francisco, California, 94143

Other trials in United States

United Kingdom4 sites
  • Research Site

    Leeds

  • Research Site

    Manchester

  • Research Site

    Oxford

  • Research Site

    Southampton

Other trials in United Kingdom

Canada2 sites
  • Research Site

    Montreal, Quebec, H4A 3J1

  • Research Site

    Vancouver, V5Z3N9

Other trials in Canada

Germany2 sites
  • Research Site

    Bonn

  • Research Site

    Tübingen

Other trials in Germany

Netherlands2 sites
  • Research Site

    Leiden

  • Research Site

    Nijmegen

Other trials in Netherlands

Finland1 site
  • Research Site

    Helsinki

Other trials in Finland

France1 site
  • Research Site

    Montpellier

Other trials in France

About this study

The objective of the study is to gain a better understanding of disease progression over time in participants with X-linked retinitis pigmentosa (XLRP).

Read the detailed description

This study was previously posted by NightstaRx Ltd. In October, 2020, sponsorship of the trial was transferred to Biogen.

Being tested
Other: Assessments
Keywords
RP GTPase regulator (RPGR), Degenerative retinal disease, XLRP, Natural history, Rare disease
Medical subject headings
Rare Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Other: AssessmentsOther

    Also called BIIB112

    Administered as specified in the treatment arm.

Study groups in NCT04926129
Study groupRoleWhat they receive
Subgroup 1Participant's eye with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) ≥74 letters (Equivalent to: Snellen 6/9 or 20/32; decimal 0.63; Logarithm of the minimum angle of resolution [LogMAR] 0.2) will be enrolled.
Receives: Other: Other: Assessments
Subgroup 2Participant's eye with ETDRS BCVA 34-73 letters, inclusive (Equivalent to: Snellen 6/12 - 6/60 or 20/40 - 20/200; decimal 0.5 - 0.1; LogMAR 0.3-1.0) will be enrolled.
Receives: Other: Other: Assessments

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA)

    BCVA will be assessed for both eyes using the ETDRS visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant.

    Measured: Up to Month 24

  2. Change from Baseline in Retinal Sensitivity Assessed with Microperimetry

    Macular analyser integrity assessment (MAIA) microperimetry will be conducted for both eyes to assess changes in retinal sensitivity within the macula.

    Measured: Up to Month 24

Secondary outcomes (17)
  1. Change from Baseline in Contrast Sensitivity

    Change from baseline in contrast sensitivity in the study eye is measured using a Pelli Robson contrast sensitivity chart at 1 meter. The contrast sensitivity chart contains letters that are darkest at the top and then get progressively lighter. Scores range from 0 to 48 and are based on the number of letters read correctly. A negative change from baseline indicates a worsening in contrast sensitivity and a positive change from baseline indicates an improvement.

    Measured: Up to Month 24

  2. Change from Baseline in Low Luminance Visual Acuity (LLVA)

    LLVA is measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. LLVA is to be reported as number of letters read correctly by the participant.

    Measured: Up to Month 24

  3. Change from Baseline in 25-item Visual Function Questionnaire (VFQ-25) Score

    VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.

    Measured: Up to Month 24

  4. Change from Baseline in Retinitis Pigmentosa (RP)-Specific Patient-Reported Outcome (PRO) Questionnaire

    Measured: Up to Month 24

  5. Change from Baseline in EuroQol-5 Dimension 5-level (EQ-5D-5L)

    The widely validated EQ-5D includes 2 components, the EQ-5D descriptive system and the EQ VAS. The EQ-5D descriptive system provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the subject is instructed to indicate whether he or she has "no problems" (level 1), "slight problems" (level 2), "moderate problems" (level 3), "severe problems (level 4), or "extreme problems/inability" (level 5) on that day. For the EQ VAS, the participant is instructed to mark an "x" on a vertical scale at the point that best describes his or her own health on that day, where 0 represents the "worst health" he or she can imagine and 100 the "best health" he or she can imagine.

    Measured: Up to Month 24

  6. Change from Baseline in Health Utilities Index Mark 3 (HUI3)

    The HUI3 is a generic 8-item survey, which provides descriptive evidence on multiple dimensions of health status, a score for each dimension of health, and a health-related quality of life score for overall health. Health dimensions include vision, hearing, speech, ambulation/mobility, pain, dexterity, emotion and cognition. Each dimension has five or six response options. Scores on individual items are combined to given a combined health state which can then be converted to health utilities. HUI3 score ranges from 0.36 (worst) to 1 (best).

    Measured: Up to Month 24

  7. Change from Baseline in Visual Field Readings

    The progression of defects in visual fields will be assessed in both eyes using perimetry equipment.

    Measured: Up to Month 24

  8. Change from Baseline in Microperimetry Readings

    MAIA microperimetry will be conducted for both eyes to assess changes other than retinal sensitivity.

    Measured: Up to Month 24

  9. Change from Baseline in Multi-Luminance Mobility Test (MLMT) Readings

    The MLMT measures changes in functional vision, as assessed by the ability to navigate a course accurately and at a reasonable pace at different levels of environmental illumination.

    Measured: Up to Month 24

  10. Change from Baseline in Spectral Domain Optical Coherence Tomography (SD-OCT)

    SD-OCT measurements will be performed after dilation of the participant's pupil.

    Measured: Up Month 24

  11. Change from Baseline in Fundus Autofluorescence (FAF)

    Fundus Autofluorescence will be performed after dilation of the participant's pupil to assess changes in the area of viable retinal tissue.

    Measured: Up to Month 24

  12. Change from Baseline in Fundus Photography

    Seven-field colour fundus photography will be used for both eyes. Fundus photography will be performed by certified technicians following pupil dilation. Stereo photos should be performed for fields 1, 2 and 3.

    Measured: Up to Month 24

  13. Change from Baseline in Adaptive-Optics Scanning Laser Ophthalmoscopy (AO-SLO)

    Measurements will be performed after dilation of the participant's pupil.

    Measured: Up to Month 24

  14. Change from Baseline in Intraocular Pressure as Assessed by Goldmann Applanation Tonometry

    Tonometry is used to measure eye pressure. After numbing the eye with eye drop anesthesia, the Goldmann tonometer presses against the eye. The force with which the eye pushes back is used to estimate the pressure inside the eye.

    Measured: Up to Month 24

  15. Change from Baseline in Morphology of Eye as Assessed by Slit-lamp Examination

    The slit lamp exam usually forms part of a comprehensive eye exam. The participant will sit in a chair facing the slit lamp with their chin and forehead resting on a support. The doctor can use this instrument to observe the eyes in detail and determine whether or not there are any abnormalities.

    Measured: Up to Month 24

  16. Change from Baseline in Morphology of Eye as Assessed by Dilated Ophthalmoscopy

    Dilated ophthalmoscopy is performed by dilating the participant's eye to see inside the fundus of the eye and other structures using an ophthalmoscope.

    Measured: Up to Month 24

  17. Change from Baseline in Morphology of Eye as Assessed by Lens Opacities Classification System (LOCS) III Lens Grading

    LOCS III is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity.

    Measured: Up to Month 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jun 2021
  2. Study start13 Sep 2017
  3. Primary completion16 Dec 2022
  4. Study completion16 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
201 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04926129
Sponsor's protocol ID
274RP001
Other IDs
NSR-XLRP-OS1
Acronym
XOLARIS
Status last verified
Feb 2023
First submitted
30 Jul 2019
Last updated
10 Feb 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • von Krusenstiern L, Liu J, Liao E, Gow JA, Chen G, Ong T, Lotery AJ, Jalil A, Lam BL, MacLaren RE; XIRIUS Part 1 Study GroupXOLARIS Study Group. Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations. JAMA Ophthalmol. 2023 Mar 1;141(3):275-283. doi: 10.1001/jamaophthalmol.2022.6254.

    PubMed 36757689

Questions about this trial

What is this clinical trial studying?

An observational study of X-Linked Retinitis Pigmentosa, run by NightstaRx Ltd, a Biogen Company at 22 sites in 7 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 22 sites in United States, United Kingdom, Canada, Germany, Netherlands and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) (time frame: Up to Month 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04926129, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in